pubmedncbinlmnihgov
Experts Agree - Tirzepatide Exposes Semaglutide's Limits
Tirzepatide currently delivers the greatest average weight loss among FDA-approved GLP-1 agents, about 20.9% of body weight in clinical trials. In the SURMOUNT-1 study, participants on a weekly 15 mg dose lost nearly a fifth of their starting weight, eclipsing the results seen with semaglutide. The drug’s dual